2021
DOI: 10.1016/j.biopsych.2021.02.086
|View full text |Cite
|
Sign up to set email alerts
|

CVN058, a 5-HT3 Receptor Antagonist, Shows Acute, Dose Dependent Improvement of Mismatch Negativity in a Double-Blind, Placebo-Controlled, Single Dose Cross-Over Study in Schizophrenia and Schizoaffective Disorder

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles